Pharmacy PEP Access Intervention Among Persons Who Use Drugs in New York City: iPEPcare Study—Rethinking Biomedical HIV Prevention Strategies

Crystal Fuller Lewis; Helen Maria Lekas; Alexis Rivera; Sharifa Z. Williams; Natalie D. Crawford; Rafael E. Pérez-Figueroa; Adriana M. Joseph; Silvia Amesty

doi:10.1007/s10461-019-02775-3

Pharmacy PEP Access Intervention Among Persons Who Use Drugs in New York City: iPEPcare Study—Rethinking Biomedical HIV Prevention Strategies

Crystal Fuller Lewis, Helen Maria Lekas, Alexis Rivera, Sharifa Z. Williams, Natalie D. Crawford, Rafael E. Pérez-Figueroa, Adriana M. Joseph, Silvia Amesty

Health, Behavior, and Society

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Biomedical HIV prevention uptake has not taken hold among Black and Latinx populations who use street-marketed drugs. A pilot intervention providing a PEP informational video and direct pharmacy access to a PEP starter dose was conducted among this population. Four study pharmacies were selected to help facilitate syringe customer recruitment (2012–2016). Baseline, post-video, and 3-month ACASI captured demographic, risk behavior, and psychosocial factors associated with PEP willingness, and willingness to access PEP in a pharmacy. A non-experimental study design revealed baseline PEP willingness to be associated with PEP awareness, health insurance, being female, and having a high-risk partner (n = 454). Three-month PEP willingness was associated with lower HIV stigma (APR = 0.95). Using a pre-post approach, PEP knowledge (p < 0.001) and willingness (p < 0.001) increased overtime; however, only three participants requested PEP during the study. In-depth interviews (n = 15) identified lack of a deeper understanding of PEP, and contextualized perceptions of HIV risk as PEP access barriers. Pharmacy PEP access shows promise but further research on perceived risk and HIV stigma is warranted.

Original language	English
Pages (from-to)	2101-2111
Number of pages	11
Journal	AIDS and Behavior
Volume	24
Issue number	7
DOIs	https://doi.org/10.1007/s10461-019-02775-3
State	Published - Jul 1 2020

Bibliographical note

Funding Information:
We would like to thank the study participants for sharing their experiences, and the study staff for their hard work. This research was sponsored by the National Institute on Drug Abuse, R01DA030253. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funders. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

Drug use
Mixed-methods
PEP
Pharmacy
Structural intervention

ASJC Scopus subject areas

Social Psychology
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10461-019-02775-3

Cite this

@article{2fbe6490e04f44ef91bb760cb6b08c2b,

title = "Pharmacy PEP Access Intervention Among Persons Who Use Drugs in New York City: iPEPcare Study—Rethinking Biomedical HIV Prevention Strategies",

abstract = "Biomedical HIV prevention uptake has not taken hold among Black and Latinx populations who use street-marketed drugs. A pilot intervention providing a PEP informational video and direct pharmacy access to a PEP starter dose was conducted among this population. Four study pharmacies were selected to help facilitate syringe customer recruitment (2012–2016). Baseline, post-video, and 3-month ACASI captured demographic, risk behavior, and psychosocial factors associated with PEP willingness, and willingness to access PEP in a pharmacy. A non-experimental study design revealed baseline PEP willingness to be associated with PEP awareness, health insurance, being female, and having a high-risk partner (n = 454). Three-month PEP willingness was associated with lower HIV stigma (APR = 0.95). Using a pre-post approach, PEP knowledge (p < 0.001) and willingness (p < 0.001) increased overtime; however, only three participants requested PEP during the study. In-depth interviews (n = 15) identified lack of a deeper understanding of PEP, and contextualized perceptions of HIV risk as PEP access barriers. Pharmacy PEP access shows promise but further research on perceived risk and HIV stigma is warranted.",

keywords = "Drug use, Mixed-methods, PEP, Pharmacy, Structural intervention",

author = "Lewis, {Crystal Fuller} and Lekas, {Helen Maria} and Alexis Rivera and Williams, {Sharifa Z.} and Crawford, {Natalie D.} and P{\'e}rez-Figueroa, {Rafael E.} and Joseph, {Adriana M.} and Silvia Amesty",

note = "Funding Information: We would like to thank the study participants for sharing their experiences, and the study staff for their hard work. This research was sponsored by the National Institute on Drug Abuse, R01DA030253. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funders. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = jul,

day = "1",

doi = "10.1007/s10461-019-02775-3",

language = "English",

volume = "24",

pages = "2101--2111",

number = "7",

}

TY - JOUR

T1 - Pharmacy PEP Access Intervention Among Persons Who Use Drugs in New York City

T2 - iPEPcare Study—Rethinking Biomedical HIV Prevention Strategies

AU - Lewis, Crystal Fuller

AU - Lekas, Helen Maria

AU - Rivera, Alexis

AU - Williams, Sharifa Z.

AU - Crawford, Natalie D.

AU - Pérez-Figueroa, Rafael E.

AU - Joseph, Adriana M.

AU - Amesty, Silvia

N1 - Funding Information: We would like to thank the study participants for sharing their experiences, and the study staff for their hard work. This research was sponsored by the National Institute on Drug Abuse, R01DA030253. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funders. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Publisher Copyright: © 2020, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Biomedical HIV prevention uptake has not taken hold among Black and Latinx populations who use street-marketed drugs. A pilot intervention providing a PEP informational video and direct pharmacy access to a PEP starter dose was conducted among this population. Four study pharmacies were selected to help facilitate syringe customer recruitment (2012–2016). Baseline, post-video, and 3-month ACASI captured demographic, risk behavior, and psychosocial factors associated with PEP willingness, and willingness to access PEP in a pharmacy. A non-experimental study design revealed baseline PEP willingness to be associated with PEP awareness, health insurance, being female, and having a high-risk partner (n = 454). Three-month PEP willingness was associated with lower HIV stigma (APR = 0.95). Using a pre-post approach, PEP knowledge (p < 0.001) and willingness (p < 0.001) increased overtime; however, only three participants requested PEP during the study. In-depth interviews (n = 15) identified lack of a deeper understanding of PEP, and contextualized perceptions of HIV risk as PEP access barriers. Pharmacy PEP access shows promise but further research on perceived risk and HIV stigma is warranted.

AB - Biomedical HIV prevention uptake has not taken hold among Black and Latinx populations who use street-marketed drugs. A pilot intervention providing a PEP informational video and direct pharmacy access to a PEP starter dose was conducted among this population. Four study pharmacies were selected to help facilitate syringe customer recruitment (2012–2016). Baseline, post-video, and 3-month ACASI captured demographic, risk behavior, and psychosocial factors associated with PEP willingness, and willingness to access PEP in a pharmacy. A non-experimental study design revealed baseline PEP willingness to be associated with PEP awareness, health insurance, being female, and having a high-risk partner (n = 454). Three-month PEP willingness was associated with lower HIV stigma (APR = 0.95). Using a pre-post approach, PEP knowledge (p < 0.001) and willingness (p < 0.001) increased overtime; however, only three participants requested PEP during the study. In-depth interviews (n = 15) identified lack of a deeper understanding of PEP, and contextualized perceptions of HIV risk as PEP access barriers. Pharmacy PEP access shows promise but further research on perceived risk and HIV stigma is warranted.

KW - Drug use

KW - Mixed-methods

KW - PEP

KW - Pharmacy

KW - Structural intervention

UR - http://www.scopus.com/inward/record.url?scp=85077523265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077523265&partnerID=8YFLogxK

U2 - 10.1007/s10461-019-02775-3

DO - 10.1007/s10461-019-02775-3

M3 - Article

C2 - 31925608

AN - SCOPUS:85077523265

VL - 24

SP - 2101

EP - 2111

IS - 7

ER -

Pharmacy PEP Access Intervention Among Persons Who Use Drugs in New York City: iPEPcare Study—Rethinking Biomedical HIV Prevention Strategies

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this